Therapeutic potential of capillary morphogenesis gene 2 extracellular vWA domain in tumour‑related angiogenesis

  • Authors:
    • Lin Ye
    • Ping-Hui Sun
    • Andrew J. Sanders
    • Tracey A. Martin
    • Jane Lane
    • Malcolm D. Mason
    • Wen G. Jiang
  • View Affiliations

  • Published online on: July 3, 2014     https://doi.org/10.3892/ijo.2014.2533
  • Pages: 1565-1573
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Capillary morphogenesis gene 2 (CMG2) is a receptor of anthrax toxin and plays an important role in angiogenesis. It has been shown to be involved in the cell adhesion and motility of various cell types, including epithelia and endothelia. The present study aimed to examine the therapeutic potential of targeting CMG2 to prevent tumour‑related new vasculature. The full-length coding sequence of the human CMG2 gene and different fragments of the CMG2 vWA domain were amplified and constructed into a mammalian expression plasmid vector. The effect of CMG2 and its vWA domain on endothelial cells and angiogenesis was assessed using relevant in vitro, ex vivo and in vivo models. The overexpression of CMG2 enhanced the adhesion of endothelial cells to extracellular matrix, but was negatively associated with cell migration. Overexpression of CMG2 and the vWA domain fragments inhibited the tubule formation and migration of endothelial cells. Small peptides based on the amino acid sequence of the CMG2 vWA domain fragments potently inhibited in vitro tubule formation and ex vivo angiogenesis. One of the polypeptides, LG20, showed an inhibitory effect on in vivo tumour growth of cancer cells which were co-inoculated with the vascular endothelial cells. CMG2 is a potential target for treating tumour‑related angiogenesis. The polypeptides based on the CMG2 vWA domain can potently inhibit in vitro and ex vivo angiogenesis, which may contribute to the inhibitory effect on in vivo tumour growth. Further investigations are required to shed light on the machinery and may provide a novel therapeutic approach for inhibition of angiogenesis in cancer management.
View Figures
View References

Related Articles

Journal Cover

October 2014
Volume 45 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ye, L., Sun, P., Sanders, A.J., Martin, T.A., Lane, J., Mason, M.D., & Jiang, W.G. (2014). Therapeutic potential of capillary morphogenesis gene 2 extracellular vWA domain in tumour‑related angiogenesis. International Journal of Oncology, 45, 1565-1573. https://doi.org/10.3892/ijo.2014.2533
MLA
Ye, L., Sun, P., Sanders, A. J., Martin, T. A., Lane, J., Mason, M. D., Jiang, W. G."Therapeutic potential of capillary morphogenesis gene 2 extracellular vWA domain in tumour‑related angiogenesis". International Journal of Oncology 45.4 (2014): 1565-1573.
Chicago
Ye, L., Sun, P., Sanders, A. J., Martin, T. A., Lane, J., Mason, M. D., Jiang, W. G."Therapeutic potential of capillary morphogenesis gene 2 extracellular vWA domain in tumour‑related angiogenesis". International Journal of Oncology 45, no. 4 (2014): 1565-1573. https://doi.org/10.3892/ijo.2014.2533